The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Dyne Therapeutics Inc shares valued at $15,968 were purchased by Kerr Douglas on Mar 05 ’25. At $11.89 per share, Kerr Douglas acquired 1,343 shares.
Also, Cox John purchased 4,067 shares, netting a total of over 48,356 in proceeds.
Before that, Beskrovnaya Oxana had added 1,094 shares to its account. In a trade valued at $13,007, the Officer bought Dyne Therapeutics Inc shares for $11.89 each.
As published in their initiating research note from Robert W. Baird on December 13, 2024, Dyne Therapeutics Inc [DYN] has been an Outperform and the price target has been revised to $46. Analysts at RBC Capital Mkts started covering the stock with ‘”an Outperform”‘ outlook in a report released in late November. As of October 24, 2024, JP Morgan has decreased its “an Overweight” rating to a “Neutral” for DYN. Earlier on May 21, 2024, Chardan Capital Markets resumed its rating. Their recommendation was “a Buy” for DYN stock.
Analyzing DYN Stock Performance
During the last five days, there has been a drop of approximately -7.06%. Over the course of the year, Dyne Therapeutics Inc shares have dropped approximately -48.05%. Shares of the company reached a 52-week high of $26.22 on 01/02/25 and a 52-week low of $11.62 on 03/04/25. A 50-day SMA is recorded $16.46, while a 200-day SMA reached $30.19.
Support And Resistance Levels for Dyne Therapeutics Inc (DYN)
According to the 24-hour chart, there is a support level at 11.86, which, if violated, would cause prices to drop to 11.48. In the upper region, resistance lies at 12.53. The next price resistance is at 12.82. RSI (Relative Strength Index) is 33.46 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -1.17, which suggests the price will decrease in the coming days. Percent R is at 78.73%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
